Bromocriptine, an antinociceptive D2 receptor agonist, is thought to reorganize an
excessively heightened hypothalamic drive for higher fatty acids, plasma glucose, and tri …

Bromocriptine mesylate quick-release was approved by the Food and Drug Administration
(FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on …

Bromocriptine is an ergot alkaloid dopamine D2 receptor agonist that has been used
extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism. It is …

Importance to the field: There is a large unmet need for new therapies to treat type 2
diabetes (T2DM) which reduce fasting and postprandial glucose without increasing insulin …

Abstract Food and Drug Administration (FDA) approved bromocriptine mesylate, a quick
release formulation, 0.8 mg tablets, as an adjunct to diet and exercise to improve glycemic …

Objective: To review the pharmacologic characteristics, safety, and efficacy of bromocriptine
mesylate for glycemic control in patients with type 2 diabetes mellitus. Data Sources: A …

Objectives: To provide an evidence-based practice overview on the clinical use of
bromocriptine-quick release (QR) across the natural history of type 2 diabetes mellitus …

An extended series of studies indicate that endogenous phase shifts in circadian neuronal
input signaling to the biological clock system centered within the hypothalamic …

D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on
animal and human studies, timed bromocriptine administration within 2 h of awakening is …

A quick-release formulation of bromocriptine is the latest drug approved by the US Food and
Drug Administration for the treatment of type 2 diabetes mellitus. Most interestingly, the …